Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire

2024-11-05

RLMD Logo.jpg

CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.

Conference Call and Webcast Information:
Date:		Thursday, November 7, 2024 at 4:30 PM ET
Participant Dial-in (US):		1-800-717-1738
Participant Dial-in (International):		1-646-307-1865
Conference ID Code:		60579
Webcast Access:		Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@lifesciadvisors.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2481557272"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481557272\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2481557272?lang=zh_CN&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tFDnGurYmaHVE9baB8jDjw--~B/aD0zMzt3PTEzMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/edd0fedcebb5e5ff70059e418ed8a363","is_english":true,"pubTime":"2024-11-05 05:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481557272","market":"us","top_or_hot":-1,"title":"Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/3hBMc7zSXt24dJpu5a.rzw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/864e8ce076842deb8ff51dcb2351bb2e\" title=\"RLMD Logo.jpg\" vspace=\"5\"/>\n<p>CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/RLMD\">Relmada Therapeutics, Inc.</a> (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"3\"><strong>Conference Call and Webcast Information</strong>:<br/></td>\n</tr>\n<tr>\n<td>Date:</td>\n<td> </td>\n<td>Thursday, November 7, 2024 at 4:30 PM ET</td>\n</tr>\n<tr>\n<td>Participant Dial-in (US):</td>\n<td> </td>\n<td>1-800-717-1738</td>\n</tr>\n<tr>\n<td>Participant Dial-in (International):</td>\n<td> </td>\n<td>1-646-307-1865</td>\n</tr>\n<tr>\n<td>Conference ID Code:</td>\n<td> </td>\n<td>60579</td>\n</tr>\n<tr>\n<td>Webcast Access:</td>\n<td> </td>\n<td>Click Here</td>\n</tr>\n</tbody>\n</table>\n<p>A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.</p>\n<p><strong>About Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. </strong></p>\n<p>Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.</p>\n<p><strong>Investor Contact: </strong><br/>Tim McCarthy <br/>LifeSci Advisors <br/>Tim@lifesciadvisors.com<br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 05:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/relmada-therapeutics-report-third-quarter-213000937.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), ...</p>\n\n<a href=\"https://finance.yahoo.com/news/relmada-therapeutics-report-third-quarter-213000937.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLMD","symbol_name":"Relmada Therapeutics, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-report-third-quarter-213000937.html","article_id":"2481557272","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tFDnGurYmaHVE9baB8jDjw--~B/aD0zMzt3PTEzMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/edd0fedcebb5e5ff70059e418ed8a363"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481557272","pubTimestamp":1730755800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system , with a focus on major depressive disorder . Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 , is a new chemical entity  and novel NMDA receptor  channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLMD":"Relmada Therapeutics, Inc.","BK4007":"制药","LENZ":"Therapeutics","ABVC":"ABVC BioPharma, Inc.","CNS":"科恩-斯蒂尔斯金融","BK4139":"生物科技","BK4135":"资产管理与托管银行"},"translate_title":"Relmada Therapeutics将于2024年11月7日报告2024年第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNS":1,"LENZ":1,"RLMD":0.9,"ABVC":0.61},"content_text":"CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.\n\n\n\nConference Call and Webcast Information:\n\n\nDate:\n \nThursday, November 7, 2024 at 4:30 PM ET\n\n\nParticipant Dial-in (US):\n \n1-800-717-1738\n\n\nParticipant Dial-in (International):\n \n1-646-307-1865\n\n\nConference ID Code:\n \n60579\n\n\nWebcast Access:\n \nClick Here\n\n\n\nA replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.\nAbout Relmada Therapeutics, Inc. \nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.\nInvestor Contact: Tim McCarthy LifeSci Advisors Tim@lifesciadvisors.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}